Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
E-pub ahead of print

Dabigatran and The Risk of Staphylococcus Aureus Bacteremia- A Nationwide Cohort Study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Altered Immune Reconstitution in Allogeneic Stem Cell Transplant Recipients With Human Immunodeficiency Virus (HIV)

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Estimation of SARS-CoV-2 infection fatality rate by real-time antibody screening of blood donors

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Risk factors and Predictors of Mortality in Streptococcal Necrotizing Soft-Tissue Infections: A Multicenter Prospective Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Hepatic steatosis associated with exposure to elvitegravir and raltegravir

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Prognosis of myocardial infarction-related cardiogenic shock according to preadmission out-of-hospital cardiac arrest

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Short-term prognosis of normalising serum potassium following an episode of hypokalaemia in patients with chronic heart failure

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Comparison of 16 Serological SARS-CoV-2 Immunoassays in 16 Clinical Laboratories

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

BACKGROUND: Treatment with dabigatran, an oral direct thrombin inhibitor, reduces the virulence of Staphylococcus aureus in in vitro and in vivo models. However, it remains to be determined whether dabigatran reduces the risk of S. aureus infections in humans. We investigated the incidence rate of Staphylococcus aureus bacteremia (SAB) in patients with atrial fibrillation treated with the direct thrombin inhibitor, dabigatran, compared with patients treated with the factor Xa-inhibitors, rivaroxaban, apixaban, and edoxaban.

METHODS: In this observational cohort study, 112,537 patients with atrial fibrillation who initiated treatment with direct oral anticoagulants (August 2011-December 2017) were identified from Danish nationwide registries. The incidence rates of SAB in patients treated with dabigatran versus patients treated with the factor Xa-inhibitors were examined by multivariable Cox regression accounting for time-dynamic changes of exposure status during follow-up.

RESULTS: A total of 112,537 patients were included. During a median follow-up of 2.0 years, 186 patients in the dabigatran group and 356 patients in the factor Xa-inhibitor group were admitted with SAB. The crude incidence rate of SAB was lower in the dabigatran group compared with the factor Xa-inhibitor group (22.8 [95%CI,19.7-26.3] and 33.8 [95%CI,30.5-37.6] events per 10.000 person-years, respectively). In adjusted analyses, dabigatran was associated with a significantly lower incidence rate of SAB compared with factor Xa-inhibitors (incidence rate ratio 0.76 [95%CI,0.63-0.93]).

CONCLUSIONS: Treatment with dabigatran was associated with a significantly lower incidence rate of SAB compared with treatment with factor Xa-inhibitors.

OriginalsprogEngelsk
TidsskriftClinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN1058-4838
DOI
StatusE-pub ahead of print - 2021

Bibliografisk note

© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

ID: 60340690